Literature DB >> 25581883

Oscillatory blood pressure response to the onset of cycling exercise in men: role of group III/IV muscle afferents.

Thales C Barbosa1, Igor A Fernandes, Nisval Magalhães, Ismar L Cavalcanti, Niels H Secher, Antonio C L Nóbrega, Lauro C Vianna.   

Abstract

NEW
FINDINGS: What is the central question of this study? Neural feedback from group III/IV muscle afferents has a key role in regulation of cardiovascular responses to exercise. Blood pressure oscillates in the first seconds of dynamic exercise, but the contribution of muscle afferent feedback to this pattern is unclear. What is the main finding and its importance? We demonstrate that attenuation of group III/IV muscle afferent feedback by spinal fentanyl impairs the pressor response after 10 s of moderate leg cycling exercise, but this afferent feedback does not appear to be necessary for induction of the oscillatory pattern of blood pressure at the onset of exercise. We investigated whether attenuation of the central projections of group III/IV skeletal muscle afferents via lumbar intrathecal administration of the μ-opioid receptor agonist fentanyl affects the oscillatory blood pressure (BP) response to the onset of dynamic exercise. Eight healthy, recreationally active men (28 ± 3 years old) performed 40 s of cycling at 80 W (60 r.p.m.) before (control) and after fentanyl administration, while heart rate, stroke volume, cardiac output, systolic, mean and diastolic BP and total vascular conductance were continuously monitored. Sytolic and mean BP responses to cycling included an initial increase (from 0 to 3 s), followed by a transient decrease below resting levels (from 3 to 10 s) and then a sustained increase (>10 s). In the presence of fentanyl, systolic and mean BP responses closely matched those in control conditions in the first 10 s, but were blunted thereafter (P < 0.05). In contrast, fentanyl did not modify the heart rate, stroke volume, cardiac output, diastolic BP or total vascular conductance responses to 40 s of cycling (P > 0.05). These findings suggest that during moderate leg cycling exercise the muscle afferents contribute to the BP response after ∼10 s, but that they do not appear to be implicated in the oscillation of BP at the onset of exercise.
© 2015 The Authors. Experimental Physiology © 2015 The Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25581883     DOI: 10.1113/expphysiol.2014.083857

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  5 in total

Review 1.  Neural control of circulation and exercise: a translational approach disclosing interactions between central command, arterial baroreflex, and muscle metaboreflex.

Authors:  Lisete C Michelini; Donal S O'Leary; Peter B Raven; Antonio C L Nóbrega
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-05-29       Impact factor: 4.733

2.  Influence of cardiac output response to the onset of exercise on cerebral blood flow.

Authors:  Shotaro Saito; Takuro Washio; Hironori Watanabe; Keisho Katayama; Shigehiko Ogoh
Journal:  Eur J Appl Physiol       Date:  2022-06-04       Impact factor: 3.346

Review 3.  The exercise pressor reflex: An update.

Authors:  André L Teixeira; Lauro C Vianna
Journal:  Clin Auton Res       Date:  2022-06-21       Impact factor: 5.625

4.  Low-dose fentanyl reduces pain perception, muscle sympathetic nerve activity responses, and blood pressure responses during the cold pressor test.

Authors:  Joseph C Watso; Mu Huang; Luke N Belval; Frank A Cimino; Caitlin P Jarrard; Joseph M Hendrix; Carmen Hinojosa-Laborde; Craig G Crandall
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-12-01       Impact factor: 3.210

5.  Intrathecal fentanyl abolishes the exaggerated blood pressure response to cycling in hypertensive men.

Authors:  Thales C Barbosa; Lauro C Vianna; Igor A Fernandes; Eliza Prodel; Helena N M Rocha; Vinicius P Garcia; Natalia G Rocha; Niels H Secher; Antonio C L Nobrega
Journal:  J Physiol       Date:  2016-01-15       Impact factor: 5.182

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.